By Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Years before Novo Nordisk's obesity drug Wegovy ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Helping compensate for the funding shortfall is the Novo Nordisk Foundation, which has pledged up to 380 Danish kroner ($58 ...

Bundled Offer Includes Wegovy® at $199 and LifeMD's Virtual Weight Loss Program for a Total First-Month Cost of $299, $599 per Month Thereafter</p ...

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

According to Evan Seigerman of BMO Capital Markets, Novo Nordisk A/S (NYSE:NVO)'s future is uncertain in the absence of a significant strategic shift. To regain its leadership in the obesity ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Septerna will also get royalties on any future product sales, The Wall Street Journal reported. Novo Nordisk will pay all the research and development costs for the project. The US biotech company ...